Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess safety and efficacy of multiple doses of NI-0801 in
primary biliary cirrhosis patients with an inadequate response to ursodeoxycholic acid.